

B<sup>2</sup> 16. (Amended) The composition of claim 13, wherein the vaccine composition comprises a peptide having the sequence given by Seq. ID No 1 or 2.

Please add claims 21-24 as follows:

21. The method of claim 12, wherein the vaccine composition comprises a peptide having the sequence given by Seq. ID No 1 or 2.

22. The method of claim 21, wherein the carrier protein is keyhole limpet hemocyanin.

B<sup>3</sup> 23. The method of claim 12, wherein the carrier protein is keyhole limpet hemocyanin.

24. The composition of claim 16, wherein the carrier protein is keyhole limpet hemocyanin.

REMARKS

Responsive to the Restriction requirement mailed January 13, 2003 for the above-captioned application, Applicants hereby elect claims 9-11 (Group II), **with traverse**. Reconsideration of the Restriction Requirement in view of the remarks herein is respectfully requested.

The Examiner has cited US Patent No. 5,550,214, and stated that this reference destroys unity of invention by disclosing a method for active peptide vaccination, wherein the immunogen is HER2/neu. The Examiner further states, without explanation, that "it would be an inherent property of the method to vaccinate against B cells.

To facilitate prosecution of this application, and without conceding the